Genmab — Maj 2020

Helge_LarsenPI-redaktør

Tak for links E L.

E_L

lol. let's put the DuoHexa up also:

E_L

DUOHEXABODY-CD37 SHOWS POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL B-CELL LYMPHOMA MODELS IN VITRO AND IN VIVO https://library.ehaweb.org/eha/2020/eha25th/293801/marije.b.overdijk.duohexabody-cd37.shows.potent.anti-tumor.activity.in.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dduohexabody

GeorgeBest

tak Pensionisten - 15:14

E_L

hang on, one more by Mrs Mateos even:

E_L

A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) https://library.ehaweb.org/eha/2020/eha25th/295026/marie-victoria.mateos.a.phase.1.study.of.teclistamab.a.humanized.b-cell.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dteclistamab

Bulder

Janssens bcma car-t har 100% ORR, 86% sCR men eet dødsfald pga CRS. http://johnsonandjohnson.gcs-web.com/static-files/8d6cdaa2-dcfb-4e49-9151-fcd8162f2df5

Bulder

Heavily pretreated pts

E_L

yes, it is getting a bit more press than the bcma/cd3. but i am glad JNJ feels comfortable showing it out now, had been so quiet about it

E_L

"CD38-knockout NK cells, which have been designed in attempt to prevent fratricide and enhance the activity of daratumumab" https://twitter.com/MM_Hub/status/1260948019689795589

Solsen

At the moment its no competitor to dara. I think we now can say no thread to dara the next 5 years either from Takeda or JNJ.

E_L

you mean the JNJ car-t?

Solsen

yes

Solsen

I still think its for the last choise - due to sideeffects (possible grade 5) and price.

E_L

yea, think so too. Jan said that from the beginning, didn't he. The market clearly overshot in car-t optimism when it first came out, where in this chat most have been relatively negative

Solsen

With Car-T you manipulate with the immune system in a way that you dont have 100% control. Some pts just suddenly die.

Solsen

Perhaps not many but to many to first, second and perhaps third line.

Solsen

And thats where the big money are.

Bulder

Nevertheless it is very positive,that in the late lines, when all other options are used, there still is a possibility to have a sCR.